Skip to content

Bivalent antibody distribution and tissue occupancy

Explore central and tissue antibody exposure and target occupancy using an independently authored nine-state mechanism and explicit synthetic parameter values.

Exploration notes · What are you exploring?

Notes stay on this browser.

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Balanced tumor access

A synthetic 30 nmol bolus probes central and tumor occupancy under nominal transport and binding assumptions.

0–480 hour

Scenario details

Balanced tumor access

A synthetic 30 nmol bolus probes central and tumor occupancy under nominal transport and binding assumptions.

Readouts

Central free antibody · nM
central free drug nM
Tumor free antibody · nM
tumor free drug nM
Central target occupancy · percent
central target occupancy percent
Tumor target occupancy · percent
tumor target occupancy percent
Total modeled antibody · nmol
total antibody nmol

Study purpose

  • How do synthetic exposure and tumor access generate a central-versus-tumor occupancy profile?

Assumptions

  • The 30 nmol input is a generic amount, not a clinical dose.
  • Occupancy is provisional and synthetic.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
480 → 168

Time between reported samples.

h
6 → 1

2 changes · Variation 1

Biology

Generic central/peripheral/tissue exchange and sequential two-site binding; all13parameters are synthetic.

Generic central/peripheral/tissue exchange and sequential two-site binding; all13parameters are synthetic.

Model details

13 parameters · 9 states · 9 equations · 11 derived outputs

Classification & API access
Therapeutic
generic bivalent tumor antibody
Modality
Monoclonal antibody
Target
configurable cell-surface target
Disease / scope
Generic solid-tumor target-engagement research
ParameterDefaultUnitDescription
Target association rateassociation_per_nM_h0.121/(nM·h)Shared synthetic association rate for the first and second target sites.
Central accessible volumecentral_volume_L3LSynthetic central volume for generic mechanism exploration.
Bound complex losscomplex_loss_h0.031/hSynthetic loss rate for singly and doubly bound complexes.
Target dissociation ratedissociation_h0.081/hShared synthetic dissociation rate for both binding steps.
Central peripheral exchange clearanceperipheral_exchange_L_h0.03L/hSymmetric concentration-driven exchange clearance.
Peripheral accessible volumeperipheral_volume_L4.5LSynthetic peripheral accessible volume.
Second site association scalesecond_site_association_scale0.6—Synthetic factor allowing the second binding step to differ from the first.
Systemic antibody clearancesystemic_clearance_L_h0.008L/hLinear central clearance of free antibody.
Central target site baselinetarget_baseline_central_nmol0.02nmolSynthetic homeostatic central target-site amount.
Tumor target site baselinetarget_baseline_tumor_nmol0.001nmolSynthetic homeostatic tumor target-site amount.
Free target turnovertarget_turnover_h0.051/hSynthetic first-order target turnover shared by central and tumor spaces.
Central tumor exchange clearancetumor_exchange_L_h0.00008L/hSynthetic tumor-access clearance used as the principal distribution control.
Tumor accessible volumetumor_volume_L0.02LSynthetic accessible tumor volume, not a patient tumor measurement.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics